Dr. Doberstein is an advisor to Acelot. He is an independent consultant to the biopharmaceutical industry, providing strategic counsel at a board level to management teams developing innovative therapeutics.

He serves as a board member on the Board of Directors for Invea Therapeutics, PARMedics, Forte Biosciences, and previously served on the board of Dicerna Therapeutics prior to its acquisition by Novo Nordisk.

His current responsibilities follow more than a decade at Nektar Therapeutics, where he served in senior R&D positions, concluding his tenure as the company’s Chief Scientist. Prior to Nektar, he served in a series of senior R&D positions at XOMA Royalty, Five Prime Therapeutics (acquired by Amgen), Xencor and Exelixis.

Dr. Doberstein earned a PhD in Bioschemistry/Molecular and Cell Biology from The Johns Hopkins University School of Medicine, and a degree in Chemical Engineering from the University of Delaware.